Oncology ADC Deals: What the Phase 2 Comp Set Actually Shows
Antibody-drug conjugates have become the most actively transacted modality in oncology licensing. But the deal benchmarks most founders reference — headline numbers from the largest ADC acquisitions — don't describe the comp set that actually applies to a Phase 2 asset. The relevant data is narrower, more specific, and tells a different story than the press releases suggest.
47 Transactions, Stratified by What Matters
We benchmarked 47 ADC licensing and acquisition transactions closed between January 2023 and June 2026, stratifying by development stage, target novelty, and payload class. The data reveals meaningful variation that headline averages obscure.
Phase 1 ADC assets (n=18) received a median upfront of $42M with total deal values averaging $680M. The wide gap between upfront and total value reflects the milestone-heavy structures that dominate early-stage ADC deals — buyers pay for optionality, not for clinical proof.
Phase 2 ADC assets (n=21) received a median upfront of $138M with total deal values averaging $1.1B. The upfront-to-total ratio at Phase 2 is 12.5% — lower than the cross-modality oncology average of 15.8%. Buyers are willing to pay more upfront for Phase 2 data, but they're also embedding more value in late-stage milestones, reflecting confidence that the clinical signal will translate.
Phase 3 and commercial-stage ADC assets (n=8) are too few to benchmark reliably, but the trend is clear: upfronts exceed $300M and deal structures shift from milestone-heavy to royalty-heavy, reflecting the transition from development risk to commercial execution risk.
ADC Median Upfront by Development Stage
Target Novelty Drives a 40% Premium
Within the Phase 2 cohort, assets targeting novel antigens — those without an approved ADC competitor — received median upfronts of $178M, compared to $127M for assets targeting validated antigens (HER2, Trop-2, Nectin-4). The 40% novelty premium reflects the strategic value of a differentiated target: the buyer isn't just acquiring an asset, they're acquiring a target franchise.
This premium has implications for how companies position during a licensing process. Leading with the target's competitive landscape — not just the clinical data — is what separates a $127M upfront from a $178M upfront when the development stage and data quality are comparable.
Phase 2 ADC Upfronts — Novel vs. Validated Targets
Payload Class Segmentation
The ADC landscape has evolved beyond the MMAE/DM1 era. Topoisomerase I inhibitor payloads (deruxtecan-class) command the highest deal values, driven by the clinical validation from established programs. Novel payload classes — immunostimulatory payloads, PBD dimers, and radioligands conjugated to antibodies — are still early but attracting significant licensing interest.
In our dataset, assets with novel payload classes received 22% lower upfronts than topoisomerase I payloads at the same development stage — but 35% higher total deal values, reflecting buyers' willingness to embed value in milestones for unproven payload-target combinations.
Relative Deal Value by Payload Class
Indexed to Topo I = 100 · controlling for stage
The Manufacturing Premium
One underappreciated factor in ADC deal economics: manufacturing readiness. Assets with established CMC packages and existing manufacturing relationships received 18% higher upfronts than assets at the same clinical stage without manufacturing clarity. The premium reflects a practical reality — ADC manufacturing is complex, capacity-constrained, and a frequent source of development delays. Buyers who can skip the manufacturing ramp-up pay more upfront to do so.
These ADC deal benchmarks are available in real-time on Solidus, our deal terms platform.
ADC DEAL COMPOSITION BY STAGE
Implications
If you're running a licensing process for a Phase 2 ADC asset, three things determine where you land in the comp set: target novelty (validated vs. novel), payload class (established vs. emerging), and manufacturing readiness. Clinical data quality matters — but it's table stakes. The positioning variables that move the needle are strategic, not clinical.
The comp set that applies to your asset is not "all ADC deals." It's the intersection of your stage, your target, and your payload class. Using the wrong comp set is how $50M of upfront value disappears in a negotiation that never should have started from the wrong benchmark.